Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 1999;33:373-377

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shah, J. R.
Right arrow Articles by Hamlyn, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shah, J. R.
Right arrow Articles by Hamlyn, J. M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*DIGOXIN
*OUABAIN

(Hypertension. 1999;33:373-377.)
© 1999 American Heart Association, Inc.


Scientific Contributions

Effects of Angiotensin II on Sodium Potassium Pumps, Endogenous Ouabain, and Aldosterone in Bovine Zona Glomerulosa Cells

Jui R. Shah; James Laredo; Bruce P. Hamilton; John M. Hamlyn

From the Departments of Physiology (J.R.S., J.M.H., J.L.) and Medicine (B.P.H.), University of Maryland, and Veterans Administration Medical Center (B.P.H.), Baltimore, Md.

Correspondence to Jui R. Shah, PhD, Department of Physiology, School of Medicine, University of Maryland at Baltimore, 655 W Baltimore St, Baltimore, MD 21201. E-mail jshah{at}umaryland.edu


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Abstract—Angiotensin (Ang) II stimulates secretions of aldosterone and an endogenous ouabain-like steroid (EO) from bovine adrenal zona glomerulosa (BAG) cells. The BAG cell sodium pump, a possible target of EO, affects aldosterone secretion although little is known about this pump. Here, we describe the effects of Ang II on the characteristics of this transporter and steroid secretions. Under serum-free conditions, 3H-ouabain bound to a single class of sites on BAG cells. Binding of label was time and concentration dependent, was sensitive to extracellular potassium ions, and was displaced by ouabain and digoxin with EC50 of {approx}218 and {approx}232 nmol/L, respectively. Sodium pump–mediated 86Rb uptake was inhibited by ouabain (EC50 {approx}301 nmol/L). Ang II dose dependently augmented secretions of EO and aldosterone, increased ouabain-sensitive 86Rb uptake and 3H-ouabain binding, and increased the affinity for 3H-ouabain binding (Kd, from 205 to 80 nmol/L) with no change in the maximal number of sodium pumps (5.45x106) per cell. Losartan blocked all effects of Ang II except EO secretion, which was inhibited by PD123319. We conclude that BAG cells express sodium pumps in high density and bind ouabain to a single class of low-affinity sites. The characteristics of the sodium pumps protect BAG cells from EO autotoxicity but may exclude them from mediating feedback inhibition of EO secretion. The effects of Ang II on sodium pump activity, ouabain binding affinity, and aldosterone secretion are mediated via Ang II type 1 receptors, whereas Ang II type 2 receptors augment EO secretion. The role of the Ang II–mediated increase in the ouabain sensitivity of BAG cell sodium pumps in the secretions of aldosterone and EO remains to be elucidated.


Key Words: cardiac glycosides • adrenal • Na,K-ATPase • secretion • cell culture


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Steroid hormones of adrenocortical origin are important regulators of cardiovascular, renal, and neural function. In addition to the classic steroid hormones, recent evidence has suggested that the adrenal cortex may secrete >=1 counterparts to the cardenolide ouabain.1 2 3 4 5 Endogenous "ouabain" (EO) is a specific, high-affinity, reversible inhibitor of sodium pumps.2 3 5 Moreover, the classic secretagogues, angiotensin (Ang) II and adrenocorticotropic hormone, raise EO secretion from primary adrenocortical cultures.6

Previously, we showed that Ang II stimulates aldosterone and EO secretions from bovine adrenal zona glomerulosa (BAG) cells via distinct receptor subtypes.7 Moreover, inhibition of sodium pumps in adrenal cells may augment aldosterone secretion.8 The apparent links between Ang II, EO, sodium pumps, and aldosterone secretion led us to characterize the sodium pump of BAG cells and investigate the effects of Ang II on the pump in concert with measurements of steroid secretion.


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Adrenocortical Cell Culture
Bovine adrenal glands were obtained from a local slaughterhouse and transported to the laboratory on ice in phosphate-buffered solution. Adrenocortical cells were dispersed and cultured according to established methods. Full details are given elsewhere.7 9 10 Cells were plated at {approx}4 million (for secretion experiments) or 1 million (for binding studies) per well. All experiments were performed with at least triplicate cell cultures.

Steroid Secretion Experiments and Radioimmunoassays
Details are given elsewhere.10 After incubation, the secretion media was collected and assayed for aldosterone and EO. They were rinsed with buffer and dissolved in 1% sodium dodecyl sulfate (SDS) for assay of total cell protein (BCA) and estimation of cell-associated radioactivity when appropriate. Aldosterone was measured with a commercially available radioimmunoassay (RIA) kit (Diagnostic Products Corp). The RIA has no cross-reactivity to ouabain or EO. Intra-assay and interassay coefficients of variation were 6.8% and 8.2%, respectively. EO was measured by RIA by use of extracted samples and a polyclonal rabbit antiouabain serum (R8) described elsewhere.11 12 The assay is highly cross-reactive with EO1 but exhibits no significant cross-reactivity (<0.01%) with cortisol, aldosterone, adrenocorticotropic hormone, and Ang II. Typical intra-assay and interassay coefficients of variation were 6.9% and 13.6%, respectively.

3H-Ouabain Binding Studies
After removal of the culture medium, the cells were washed twice with buffer (containing in mmol/L NaCl 145, KCl 5, CaCl2 2, MgCl2 1, glucose 10, HEPES 10-NaOH, pH 7.4). Buffer containing 3H-ouabain (10 to 300 nmol/L) either alone or with pharmacological reagents was added to the cells and incubated at 37°C in 5% CO2 for 4 or 8 hours. For nonspecific binding, 30 µmol/L cold ouabain was present in the buffer, and specific binding was taken as the difference between total and nonspecific binding. Competition curves for 3H-ouabain binding were constructed by use of 10 nmol/L 3H-ouabain in the presence of increasing amounts of cold ouabain. At the end of the experiment, cells were rinsed with buffer and dissolved in 1% SDS. Total cell protein (BCA) and cell-associated radioactivity were determined.

86Rb Uptake Studies
The culture medium was removed, and the cells were washed twice with a secretion buffer containing 2 mmol/L RbCl. Secretion buffer fortified with 86RbCl (0.11 mmol/L) and various pharmacological agents was incubated with cells at 37°C in 5% CO2 for 4 hours. The medium was aspirated, and cells were rinsed 3 times in 2 mL ice-cold buffer with 2 mmol/L RbCl and mixed with 1 mL of 1% SDS for assay of total cell protein and cell-associated 86Rb (gamma counter). Pump activity was the difference between uptake in the absence and presence of 0.1 mmol/L ouabain. Pump fluxes are expressed as nanomoles of Rb plus potassium per milligram per 4 hours.

Materials
PD123319-ditrifluoroacetate (DTFA) was a gift of Dr David Taylor (Warner-Lambert, Ann Arbor, Mich). DTFA was removed by high-performance liquid chromatography before use. Losartan (DuP 753) was a gift of Dr Ronald Smith (Du Pont Merck). Collagenase type I and DNase type I were from Worthington Biochemicals. Percoll was from Pharmacia. Fetal bovine serum and Dulbecco's modified Eagle's medium were from GIBCO-BRL. 3H-ouabain was from New England Nuclear. Other chemicals were from Sigma Chemical Co.

Statistical Analyses
Evaluations of significance were performed with ANOVA and Fisher's specific test. Results were expressed as mean±SEM, and P<0.05 was used to indicate significance unless otherwise noted.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
Characterization of BAG Cell Sodium Pumps
Figure 1Down shows the time course, concentration dependence, and potassium sensitivity of 3H-ouabain binding to BAG cells. In the time course and concentration experiments, specific binding was >90% of the total. Specific binding increased fairly linearly with time. The concentration dependence of specific binding was unexpectedly linear, showing no clear evidence of saturation even at 300 nmol/L. These results suggested that the sodium pumps in these cells had fairly low affinity for ouabain. In addition, specific ouabain binding was reduced dose dependently by extracellular potassium over the range of 0.01 to 10 mmol/L. The dose-response curve for potassium ions was shifted {approx}7.5-fold rightward when binding was performed in 100 instead of 10 nmol/L 3H-ouabain.



View larger version (25K):
[in this window]
[in a new window]
 
Figure 1. Time, concentration, and potassium dependence of 3H-ouabain binding to BAG cells. Top, Time course for binding of 50 nmol/L 3H-ouabain alone (total) or also containing 30 µmol/L cold ouabain (nonspecific). Calculated specific binding (specific) is shown. Each point is mean±SEM of >=3 culture wells. Middle, Concentration dependence of 3H-ouabain binding to cells. Total, nonspecific, and calculated specific binding are shown. BAG cells were incubated for 8 hours with increasing concentrations of 3H-ouabain. Bottom, Effect of extracellular potassium concentration on specific binding of 10 and 100 nmol/L 3H-ouabain. Points are mean±SEM of >=3 culture wells. Where SEM values are not shown, they are smaller than symbol size.

To explore the binding affinity of the sodium pumps for cardiac glycosides, the cells were coincubated with increasing doses of cold cardiac glycosides in the presence of tracer amounts (10 nmol/L) of 3H-ouabain. As shown in Figure 2Down, binding of 3H-ouabain was displaced in a concentration-dependent manner by both ouabain and digoxin with IC50 of {approx}218 and {approx}232 nmol/L, respectively. In each case, the Hill coefficients were nearly unity, indicating the interaction of ouabain and digoxin with a single class of 3H-ouabain binding sites.



View larger version (21K):
[in this window]
[in a new window]
 
Figure 2. Effects of ouabain, digoxin, and Ang II (AII in figure) on 3H-ouabain binding to BAG cells. Top, Cells were incubated with 10 nmol/L 3H-ouabain and indicated concentrations of cold ligand ({bullet}, ouabain; {blacksquare}, digoxin). Curves were fitted iteratively to 4-parameter equation (Hamlyn et al1 ). Calculated EC50 for ouabain and digoxin was 218 and 232 nmol/L, respectively. SEM values are smaller than symbol size. Bottom, Cells were incubated 4 hours with 50 nmol/L 3H-ouabain in presence of various doses of Ang II. Shown is total, nonspecific, and calculated specific binding. All points are mean±SEM of >=3 separate cultures.

Rb+ ions substitute for K+ in stimulating ATP hydrolysis and sodium pump–mediated transport into cells. Preliminary experiments showed that BAG cells accumulated 86Rb and that the ouabain-sensitive component comprised >80% of the uptake over 4 hours (data not shown).

Effects of Ang II Receptors on Ouabain Binding and Sodium Pump Activity
The effect of Ang II on the binding of 3H-ouabain to BAG cells is shown in Figure 2Up. Ang II dose dependently increased the specific binding of 3H-ouabain to BAG cells from a basal of {approx}6 to >14 fmol/mg at 100 nmol/L Ang II. The EC50 for Ang II stimulation of 3H-ouabain binding was {approx}1 nmol/L. This value is similar to the EC50 for the stimulation of corticosteroid secretions,7 suggesting that the same receptor may be involved in both effects.

Further experiments in which the concentration of 3H-ouabain was systematically varied showed that the effect of Ang II increased the binding of label at all concentrations tested (Figure 3Down). Moreover, Scatchard analysis (Figure 3Down, inset) showed that the binding of 3H-ouabain to BAG cells under basal conditions was well fit to a single class of binding sites with an apparent Kd of 205 nmol/L, and a Bmax of 35.6 fmol/µg protein. In the presence of 10 nmol/L Ang II, a single class of binding sites was again detected whose dissociation constant and maximal binding were 79 nmol/L and 35.9 fmol/µg, respectively. Thus, Ang II increased the sensitivity of the sodium pumps to ouabain {approx}3-fold without changing their number.



View larger version (24K):
[in this window]
[in a new window]
 
Figure 3. Concentration dependence of specific 3H-ouabain binding to BAG cells and effect of Ang II. Cells were incubated for 4 hours with various concentrations of 3H-ouabain as indicated in presence and absence of 10 nmol/L Ang II. Data are means of 4 separate wells. Typical errors were <3%. Inset, Scatchard plot of data fit by iterative regression. Kd was 205±14 and {approx}79±9 nmol/L for control and Ang II, respectively. Bmax was 35.6 and 35.9 fmol/µg protein for control and Ang II, respectively.

Figure 4Down shows the effects of specific blockade of Ang II type 1 and 2 receptors on 3H-ouabain binding and sodium pump activity (as estimated by ouabain-sensitive 86Rb uptake). Ang II augmented 3H-ouabain binding and increased sodium pump activity. In parallel incubations, Ang II stimulated (P<0.05) the secretions of aldosterone (basal, 0.82±0.08 pmol · mg-1 · 2 h-1; Ang II, 5.68±0.57 pmol · mg-1 · 2 h-1) and EO (basal, 0.64±0.04 pmol · mg-1 · 2 h-1; Ang II, 1.5±0.09 pmol · mg-1 · 2 h-1). Except for EO secretion, all effects of Ang II were blocked by losartan. In contrast, PD123319 specifically inhibited Ang II–stimulated EO secretion. Neither losartan nor PD123319 affected the measured parameters in the absence of Ang II (not shown).



View larger version (19K):
[in this window]
[in a new window]
 
Figure 4. Role of Ang II (AII in figure) type 1 and 2 receptors in Ang II–stimulated ouabain-sensitive 86Rb+K uptake and 3H-ouabain binding. Top, Cells were incubated with 86RbCl (0.11 mmol/L) in buffer alone (basal) or containing Ang II (10 nmol/L), Ang II+losartan (Los, 10 µmol/L), or Ang II+PD123319 (2 µmol/L) with or without 0.1 mmol/L cold ouabain for 4 hours. (Data with antagonists alone were not different from basal and are not shown.) Data are mean±SEM of ouabain-sensitive 86Rb+K flux from 3 culture wells. Bottom, Data from cells incubated 4 hours with 50 nmol/L 3H-ouabain. Similar conditions as top.


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
The present investigation was prompted by several observations. First, BAG cells were shown to secrete aldosterone and EO.7 9 10 Second, EO was known to be a high-affinity and specific inhibitor of the sodium potassium pump.2 Third, many reports indicated that ouabain and other sodium pump inhibitors may affect aldosterone secretion.8 13 14 15 16 17 18 19 Fourth, part of the effect of Ang II on aldosterone secretion was suggested to involve inhibition of adrenocortical sodium pumps.8 Fifth, the kinetics of EO secretion implied autoinhibition, perhaps mediated by sodium pumps.6 Sixth, the characteristics of the sodium pumps in primary cell cultures of BAG cells used by our laboratory and others were not known. Collectively, these observations suggested that the secretion and subsequent binding of EO to adrenocortical sodium pumps might have multiple consequences. Accordingly, we investigated the sodium pump of the BAG to evaluate its properties and possible roles in the Ang II–stimulated secretions of EO and aldosterone. Measurements of aldosterone secretion were used for correlative and comparative purposes and to demonstrate the functional integrity of this secretory system.

Under basal conditions, both the time and concentration dependence of 3H-ouabain binding were pseudolinear (Figure 1Up). This is consistent with the use of ligand concentrations that are significantly less than the receptor affinity. More than 90% of the total binding was specific. The concentration dependence of specific binding showed no evidence of saturation even at 300 nmol/L. Changes in potassium ion concentration within the physiological range reduce the affinity for cardiac glycoside binding to the sodium pump. The marked potassium ion sensitivity of the interaction of 3H-ouabain with BAG cells and the weakened effect of potassium at the highest concentration of 3H-ouabain used show that specific binding is mediated exclusively by sodium pumps. Further analysis of the relationship showed that the competition between labeled and cold ouabain occurred at a single class of binding sites whose apparent affinity for ouabain and digoxin was surprisingly low (Figure 2Up). These results, consistent with the temporal and concentration data in Figure 1Up, have other implications. We suggested previously that feedback inhibition of EO secretion may be mediated by autoreceptors.6 The present results suggest that these autoreceptors are not sodium pumps. For example, the rate of EO secretion falls to {approx}10% of the initial rate as the concentration of secreted EO rises into the range of 0.2 to 0.5 nmol/L.6 On the basis of a binding affinity for ouabain of {approx}200 nmol/L and with equivalent potency assumed, an EO concentration of 0.5 nmol/L would bind and inhibit <=0.25% of the bulk sodium pumps. Another possibility is that a small number of specialized pumps are involved. In some cell types, small numbers of sodium pumps with high ouabain affinity are clustered in functional microdomains over portions of the sarcoplasmic reticulum. In vascular smooth muscle cells, nanomolar concentrations of ouabain interact specifically with these pumps to affect stored calcium, while leaving other sodium pumps involved in the control of bulk cytosolic sodium unaffected.20 If such specialized sodium pumps or other types of ouabain receptors were present in BAG cells, they would comprise <5% of the specific binding sites measured and would escape detection by our methods.

Another factor of relevance to BAG cell function is the high density (5.45x106) of sodium pumps per cell estimated from Scatchard analysis (Figure 3Up). This is reminiscent of tissues such as nerve, heart, and kidney in which the high copy number typically is associated with large inward sodium fluxes and high rates of aerobic metabolism. Moreover, it is consistent with other reports that have noted high Na,K-ATPase activity in glomerulosa tissue.8 21

What is the possible significance of high pump turnover, low affinity, and high pump densities? In other systems in which a ligand may be present continuously, rapid receptor turnover can serve as a means to alter signaling. The concentration of EO leaving the dog adrenal is {approx}0.75 nmol/L, roughly 4- to 5-fold higher than that entering the gland.12 Moreover, the local intra-adrenal concentrations of EO, in the vicinity of the secretory cells especially during Ang II stimulation, may be 10-fold higher than those measured in the mixed venous effluent. Even under these conditions, our calculations suggest that <=12% to 15% of the available pumps could be occupied by EO. This level of pump blockade would be expected to cause physiologically relevant increases in cell sodium and stored calcium that would augment signaling by Ang II and other stimulants without toxicity. The affinity of the adrenocortical sodium pump for cardiac glycosides in cows, coupled with a high pump density, is poised for physiological regulation by EO while forestalling the potential for autotoxicity in the adrenocortical environment.

Previous reports of the effects of Ang II on sodium pump activity in adrenocortical cells are varied. In rat glomerulosa cells and bovine adrenal cells, Ang II was thought to inhibit sodium pumps.8 16 Exposure of cells to Ang II does not appear to affect the Na,K-ATPase activity in isolated membranes.21 22 Consistent with this impression, our results showed that Ang II, via Ang II type 1 receptors, increased both the affinity of BAG sodium pumps for ouabain and their transport activity (Figure 4Up) without upregulation or downregulation of surface membrane pump number (Figure 3Up). The increase in pump activity in response to Ang II probably originates from an increase in cell sodium,23 which is known to enhance the formation of a phosphorylated intermediate of the pump1 whose affinity for ouabain is heightened simultaneously.

The increased EO secretion occurring at a time when the ouabain affinity of the BAG cell sodium pump is increased, along with the demand for heightened active transport, seems paradoxical (Figures 3Up and 4Up). One possibility is that intra-adrenal EO might augment Ang II–stimulated aldosterone secretion. In rat adrenal cells, aldosterone secretion was increased during inhibition of sodium pumps by both Ang II and ouabain.8 In other species, some studies reported inhibition,13 14 15 17 stimulation,24 or transient stimulation followed by inhibition17 18 of aldosterone secretion in response to ouabain. Studies that observed inhibition of aldosterone secretion have in general used pharmacological concentrations of ouabain that would inhibit >50% of the available sodium pumps. These conditions are often lethal because the activity of the residual pumps cannot increase sufficiently to normalize outward sodium flux and cell potassium.

Two recent sets of observations suggest that aldosterone secretion can be augmented by concentrations of ouabain that could inhibit no more than a small portion of the bulk sodium pumps. In the rat, continuous infusions of ouabain for 5 weeks resulted in circulating plasma levels ranging from {approx}1 to 5 nmol/L. Under these conditions, plasma aldosterone was dose dependently elevated, whereas plasma renin activity was unchanged.19 Thus, low concentrations of ouabain approaching the physiological range of EO provide a strong in vivo stimulus to aldosterone secretion in the rat. A similar result, albeit with pharmacological concentrations of ouabain, has been observed with rat BAG cells in vitro.25 In addition, Tamura et al26 have shown that ouabain at 10 nmol/L increased basal aldosterone secretion 2- to 3-fold from bovine adrenocortical cells in culture and enhanced Ang II–stimulated secretion. Assuming that their cells exhibited sodium pumps whose characteristics were similar to those we observed, our calculations suggest that the binding of ouabain to <=15% of the available sodium pumps is sufficient to augment aldosterone secretion significantly.

Elevated circulating levels of EO and aldosterone have been described in {approx}50% of hypertensive patients with surgically confirmed Conn's syndrome.27 These observations, along with those mentioned above and the accumulating evidence that the secretions of EO and aldosterone are regulated differently,7 10 raise the possibility that the hyperaldosteronism in some patients with Conn's syndrome may be secondary to a primary overproduction of EO. New classes of agents that block ouabain and EO binding may distinguish among these patients.28


*    Acknowledgments
 
This work was supported by the American Heart Association (Drs Shah and Hamlyn) and in part by the National Institutes of Health.


*    Footnotes
 
Dr Laredo is now at the Department of Surgery, Beth Israel Hospital, Harvard University, 330 Brookline Ave, Boston, MA 02215.

Received September 18, 1998; first decision October 19, 1998; accepted November 6, 1998.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
up arrowDiscussion
*References
 
1. Hamlyn JM, Harris DW, Ludens JH. Digitalis-like activity in human plasma: purification, affinity and mechanism. J Biol Chem. 1989;264:7395–7404.[Abstract/Free Full Text]

2. Hamlyn JM, Blaustein MP, Bova S, DuCharme DW, Harris DW, Mandel F, Mathews WR, Ludens JH. Identification and characterization of a ouabain-like compound from human plasma. Proc Natl Acad Sci U S A. 1991;88:6259–6263.[Abstract/Free Full Text]

3. Schoner W, Heidrich-Lorsbach E, Kirch U, Ahlemeyer B, Sich B. Purification and properties of endogenous ouabain-like substances from hemofiltrate and adrenal glands. J Cardiovasc Pharmacol. 1993;22:S29–S31.

4. Shaikh IM, Lau BWC, Siegfried BA, Valdes R. Isolation of digoxin-like immunoreactive factors from mammalian adrenal cortex. J Biol Chem. 1991;266:13672–13678.[Abstract/Free Full Text]

5. Tamura M, Lam T, Inagami T. Isolation and characterization of a specific endogenous Na+,K+-ATPase inhibitor from bovine adrenal. Biochemistry. 1988;27:4244–4253.[Medline] [Order article via Infotrieve]

6. Laredo J, Hamilton BP, Hamlyn JM. Ouabain is secreted by bovine adrenocortical cells. Endocrinology. 1994;135:794–797.[Abstract]

7. Laredo J, Shah JR,. Lu Z-R, Hamilton BP, Hamlyn JM. Angiotensin II stimulates secretion of endogenous ouabain from bovine adrenocortical cells via angiotensin type 2 receptors. Hypertension. 1997;29(pt 2):401–407.

8. Hajnoczky G, Csordas G, Hunyady L, Kalapos MP, Balla T, Enyedi P, Spat A. Angiotensin II inhibits Na+/K+ pump in rat adrenal glomerulosa cells: possible contribution to stimulation of aldosterone production. Endocrinology. 1992;130:1637–1644.[Abstract/Free Full Text]

9. Laredo J, Hamilton BP, Hamlyn JM. Secretion of endogenous ouabain from bovine adrenocortical cells: role of the zona glomerulosa and zona fasciculata. Biochem Biophys Res Commun. 1995;212:487–493.[Medline] [Order article via Infotrieve]

10. Shah JR, Laredo J, Hamilton BP, Hamlyn JM. Different signaling pathways mediate stimulated secretion of endogenous ouabain and aldosterone from bovine adrenocortical cells. Hypertension. 1998;31:463–468.[Abstract/Free Full Text]

11. Harris DW, Clark MA, Fisher JF, Hamlyn JM, Kolbasa KP, Ludens JH, DuCharme D. Development of an immunoassay for endogenous digitalis-like factor. Hypertension. 1991;7:936–943.

12. Boulanger BR, Lilly MP, Hamlyn JM, Laredo J, Shurtleff D, Gann DS. Ouabain is secreted by the adrenal gland in awake dogs. Am J Physiol;. 1993;264:E413–E419.

13. Antonipillai I, Schick K, Horton R. Ouabain is a potent inhibitor of aldosterone secretion and angiotensin action in the human adrenal. J Clin Endocrinol Metab. 1996;81:2335–2337.[Abstract]

14. Cushman P. Inhibition of aldosterone secretion by ouabain in dog adrenal cortical tissue. Endocrinology. 1969;84:808–813.[Abstract/Free Full Text]

15. Elliot ME, Hadjokas NE, Goodfriend TE. Effects of ouabain and potassium on protein synthesis and angiotensin-stimulated aldosterone synthesis in bovine adrenal glomerulosa cells. Endocrinology. 1986;118:1469–1475.[Abstract/Free Full Text]

16. Kenyon CJ, Shepherd RM, Fraser R, Pediani JD, Elder HY. The role of potassium and other ions in the control of aldosterone synthesis. Endocr Res. 1991;17:225–236.[Medline] [Order article via Infotrieve]

17. Nakajima S, Suzuki H, Saito I, Saruta T. Effects of atrial natriuretic peptide, dopamine and ouabain on aldosterone synthesis. Acta Endocrinolog. 1987;115:57–62.

18. Szalay KS. The effect of ouabain on aldosterone production in the rat. Acta Endocrinolog. 1971;68:477–484.

19. Manunta P, Rogowski AC, Hamilton BP, Hamlyn JM. Ouabain-induced hypertension in the rat: relationships among circulating and tissue ouabain and blood pressure. J Hypertens. 1994;12:549–560.[Medline] [Order article via Infotrieve]

20. Juhaszova M, Blaustein MP. Na+ pump low and high ouabain affinity alpha subunit isoforms are differently distributed in cells. Proc Natl Acad Sci U S A. 1997;94:1800–1805.

21. Meuli C, Muller J. Characterization of rat capsular adrenal (zona glomerulosa) Na,K-ATPase activity. J Steroid Biochem Mol Biol. 1982;16:129–132.

22. Douglas J, Saltman S, Williams C, Bartley P, Kondo T, Catt K. An examination of possible mechanisms of angiotensin II-stimulated steroidogenesis. Endocr Res. 1978;5:173–188.

23. van der Bent V, Demole C, Johnson EI, Rossier MF, Python CP, Vallotton MB, Capponi AM. Angiotensin-II induces changes in the cytosolic sodium concentration in bovine adrenal glomerulosa cells: involvement in the activation of aldosterone biosynthesis. Endocrinology. 1993;133:1213–1220.[Abstract/Free Full Text]

24. Szalay KS. Ouabain: a local, paracrine, aldosterone synthesis regulating hormone? Life Sci. 1993;52:1777–1780.[Medline] [Order article via Infotrieve]

25. Szalay KS, Beck M, Toth M, de Chatel R. Interactions between ouabain, atrial natriuretic peptide, angiotensin II and potassium: effects on rat zona glomerulosa aldosterone production. Life Sci. 1998;62:1845–1852.[Medline] [Order article via Infotrieve]

26. Tamura M, Piston DW, Tani M, Naruse M, Landon EJ, Inagami T. Ouabain increases aldosterone release from bovine adrenal glomerulosa cells: role of renin-angiotensin system. Am J Physiol. 1996;270:E27–E35.[Abstract/Free Full Text]

27. Rossi GP, Manunta P, Hamlyn JM, Pavan E, De Toni R, Semplicini A, Pessina AC. Immunoreactive endogenous ouabain in primary aldosteronism and essential hypertension: relationship with plasma renin, aldosterone and blood pressure levels. J Hypertens. 1995;13:1181–1191.[Medline] [Order article via Infotrieve]

28. Goto A, Yamada K. An approach to the development of novel antihypertensive drugs: potential role of sodium pump inhibitors. Trends Pharmacol Sci. 1998;19:201–204.[Medline] [Order article via Infotrieve]




This article has been cited by other articles:


Home page
Pharmacol. Rev.Home page
A. Y. Bagrov, J. I. Shapiro, and O. V. Fedorova
Endogenous Cardiotonic Steroids: Physiology, Pharmacology, and Novel Therapeutic Targets
Pharmacol. Rev., March 1, 2009; 61(1): 9 - 38.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
E. Shibata, R. W. Powers, A. Rajakumar, F. von Versen-Hoynck, M. J. Gallaher, D. L. Lykins, J. M. Roberts, and C. A. Hubel
Angiotensin II decreases system A amino acid transporter activity in human placental villous fragments through AT1 receptor activation
Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E1009 - E1016.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
H. M.A.M. Qazzaz, Z. Cao, D. D. Bolanowski, B. J. Clark, and R. Valdes Jr
De Novo Biosynthesis and Radiolabeling of Mammalian Digitalis-Like Factors
Clin. Chem., March 1, 2004; 50(3): 612 - 620.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
M. A. El-Masri, B. J. Clark, H. M. Qazzaz, and R. Valdes Jr
Human Adrenal Cells in Culture Produce Both Ouabain-like and Dihydroouabain-like Factors
Clin. Chem., October 1, 2002; 48(10): 1720 - 1730.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
R. I. Dmitrieva and P. A. Doris
Cardiotonic Steroids: Potential Endogenous Sodium Pump Ligands with Diverse Function
Experimental Biology and Medicine, September 1, 2002; 227(8): 561 - 569.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
Y. Hou and N. A. Delamere
Influence of ANG II on cytoplasmic sodium in cultured rabbit nonpigmented ciliary epithelium
Am J Physiol Cell Physiol, August 1, 2002; 283(2): C552 - C559.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
H. Wang and F. H.H. Leenen
Brain Sodium Channels Mediate Increases in Brain "Ouabain" and Blood Pressure in Dahl S Rats
Hypertension, July 1, 2002; 40(1): 96 - 100.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shah, J. R.
Right arrow Articles by Hamlyn, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shah, J. R.
Right arrow Articles by Hamlyn, J. M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*DIGOXIN
*OUABAIN